Description
On this episode, Greg is joined by Herman De Prins, Global CIO of biopharma company UCB. Herman describes UCB’s journey into artificial intelligence (AI), which began with projects aimed at treatments for epilepsy. Herman also shares how UCB promoted data literacy and AI among its staff of more than 8,000 people worldwide, and how the company prioritizes the many projects brought forward by its team of AI enthusiasts. Herman emphasized that there is value in AI across the pharmaceutical value chain, particularly in R&D and commercial. For example, last year UCB used AI to conduct research on potential treatments for COVID-19 and reduced the time typically required for that research from six months to three days. Greg and Herman conclude their chat by discussing the future of AI and Herman’s thoughts on the potential opportunities and pitfalls in a world where AI will increasingly be embedded in technology products all around us.
Dr. James Hildreth, MD, PhD, President and CEO of Meharry Medical College, is a passionate leader speaking about health equity, the power of AI in medicine and how aspiring physicians can be supported throughout their studies. In this episode, Hildreth speaks about the influence of social...
Published 10/01/24
Dr. Onyi Daniel, Sinai Health System Board Member and former Vice President for Data and Analytics Strategy at Highmark Health, is a passionate health tech leader who speaks about change management, AI use cases, health equity and the importance of responsible AI.
In this episode, Daniel shares...
Published 09/10/24